EUPROTEIN has developed high-quality human GFAP proteins that could be used for diagnostic assay development. Only $99 for 25ug!
Glial fibrillary acidic protein (GFAP) is an intermediate filament (IF) protein that is expressed by numerous cell types of the central nervous system (CNS) including astrocytes and ependymal cells during development. It is closely related to its non-epithelial family members, vimentin, desmin, and peripherin, which are all involved in the structure and function of the cell’s cytoskeleton.
Some researchers have suggested that astroglial cells play an important role in the functioning of other cells, including specialized cells that surround nerves (oligodendrocytes) and are involved in the production and long-term maintenance of myelin. Myelin is the fatty substance that forms a protective coating around certain nerve cells and ensures the rapid transmission of nerve impulses. Additionally, astroglial cells may assist in maintaining the protective barrier that allows only certain substances to pass between blood vessels and the brain (the blood-brain barrier).
Researchers have identified more than 50 GFAP mutations that cause Alexander disease. Alexander disease is a rare disorder of the nervous system. It is one of a group of disorders, called leukodystrophies, that involve the destruction of myelin. Myelin is the fatty covering that insulates nerve fibers and promotes the rapid transmission of nerve impulses. If myelin is not properly maintained, the transmission of nerve impulses could be disrupted. As myelin deteriorates in leukodystrophies such as Alexander disease, nervous system functions are impaired.
GFAP is also shown as a potential biomarker for traumatic brain injury (TBI). Despite growing recognition and research of the importance and potential of biomarkers for TBI, there are currently no FDA-cleared or approved objective blood tests for TBI or concussion. GFAP, Ubiquitin C-terminal hydrolase-L1 (UCHL1), and S100 calcium-binding protein B (S100B) are novel biomarker candidates that are highly brain specific and are detectable in the serum shortly after TBI. A study published in 2019 that included 37 controls and 118 unique trauma subjects has indicated that GFAP, UCHL1, and S100B demonstrated utility for rapid prediction of a CT-positive TBI within 0-8 hours of injury; GFAP exhibited the greatest predictive power at 12-32 hours. Furthermore, these results suggest that GFAP alone has greater utility for predicting a positive CT of the head than UCHL1, S100B, or any combination of the 3 biomarkers.
EUPROTEIN has developed high-quality human GFAP proteins that could be used for diagnostic assay development.
These proteins are on sale now, only $99 for 25ug! Place order now.
If you would like to express the GFAP or UCHL1 protein or generating antibodies against them, please submit your inquiry.